The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Challenges and opportunities with modelling and simulation in drug discovery and drug development
Abstract
The benefits of modelling and simulation at the pre-clinical stage of drug development can be realized through formal and realistic integration of data on physicochemical properties, pharmacokinetics, pharmacodynamics, formulation and safety. Such data integration and the powerful combination of physiologically based pharmacokinetic (PBPK) with pharmacokinetic-pharmacodynamic relationship (PK/PD) models provides the basis for quantitative outputs allowing comparisons across compounds and resulting in improved decision-making during the selection process. Such PBPK/PD evaluations provide crucial information on the potency and safety of drug candidates in vivo and the bridging of the PK/PD concept established during the pre-clinical phase to clinical studies. Modelling and simulation is required to address a number of key questions at the various stages of the drug-discovery and -development process. Such questions include the following. (1) What is the expected human PK profile for potential clinical candidate(s)? (2) Is this profile and its associated PD adequate for the given indication? (3) What is the optimal dosing schedule with respect to safety and efficacy? (4) Is a food effect expected? (5) How can formulation be improved and what is the potential benefit? (6) What is the expected variability and uncertainty in the predictions?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (1909) · JAMA · doi:10.1001/jama.1909.02550020033007 · Cited by 7,889
Self-citation(2024) · Pharmacological Reviews · doi:10.1124/pr · Cited by 2,680
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami‐Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 533
Ito, K., Iwatsubo, T., Kanamitsu, S.-I., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 511
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
Self-citationDiversity of Mechanism-Based Pharmacodynamic Models
Mager, D. E., Wyska, E., & Jusko, W. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.510 · Cited by 345
Comparison of Canine and Human Gastrointestinal Physiology
Dressman, J. (1986) · Pharmaceutical Research · doi:10.1023/a:1016353705970 · Cited by 339
Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices
Houston, J. B., & Carlile, D. J. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709002237 · Cited by 304
Whole Body Pharmacokinetic Models
Nestorov, I. A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342100-00002 · Cited by 290
Research works printed but not linked: 2
- Bangs A, 2005, Studies in Health Technology Information, 111, 37
- Jones HM, 2005, Paper presented at the PAGE 16th Conference 2005
Cited by
Sorted by citations
Items 101–115 of 115
Mechanism‐Based Pharmacokinetic–Pharmacodynamic Modeling During Discovery and Early Development
Grimm, H. P., Ou, Y. C., Reddy, M. B., David‐Pierson, P., & Lavé, T. (2011) · doi:10.1002/9781118016435.ch8
Self-citationTransporters in Drug Discovery
El‐Kattan, A. F., Varma, M. V. S., & Lai, Y. (2014) · doi:10.1002/9781118705308.ch19
Alvarez, H. A. (2016) · OakTrust (Texas A&M University Libraries)
Role of the Vitamin D Receptor in MDR1/P-glycoprotein Regulation at the Blood-brain Barrier
Durk, R. M. (2014) · TSpace (University of Toronto)
Berry, P., Parrott, N. J., Reddy, M. B., David‐Pierson, P., & Lavé, T. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch10
Self-citationPHARMACOKINETICS AND TOXICOKINETICS IN DRUG SAFETY EVALUATION
Gad, S. C., & Sullivan, D. W. (2022) · doi:10.1002/9781119755883.ch19
PBPK modeling for early clinical study decision making
Riedmaier, A. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00014-3
SMCVdb: a database of experimental cellular toxicity information for drug candidate molecules
Pandey, A. D., Sharma, G., Sharma, A., Vrati, S., & Nair, D. T. (2024) · Database · doi:10.1093/database/baae100
Drug Discovery and Development Process
Hande, A., & Chambhare, N. (2024) · DMIHER International Conference on Artificial Intelligence in Healthcare, Education and Industry (IDICAIHEI) · doi:10.1109/idicaiei61867.2024.10842909
In Silico Identification of Multi-Target Ligands for Neurodegenerative Disorders
Sharma, A. K., Batra, I., & Malik, A. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-4627-4.ch006
Prediction of Protein–Ligand Binding Affinities Using Atomic Surface Site Interaction Points
Zator, K. J., Storer, M. C., & Hunter, C. A. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02628
Pharmacokinetics and pharmacodynamics in cancer pharmacology
Aparna, T. N., Wal, P., Puri, S. U., & Pandya, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00008-x
Zhou, J. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Metadata
- Authors
- Lavé, T., Parrott, N., Grimm, H. P., Fleury, A., & Reddy, M.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Roche (United States) (US)
- Venue
- Xenobiotica
- Publisher
- Informa UK Limited
- Published
- 2007-11
- Volume
- 37
- Issue
- 10-11
- Pages
- 1295-1310
- ISSN
- 0049-8254 (ISSN-L)
- 1366-5928
- OpenAlex
- W1994206407
- Cited by
- 115
- References
- 47
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 2 · 2014: 11 · 2013: 6 · 2012: 9
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Xenobiotica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- modeling and simulation, drug discovery, drug development, physiologically based pharmacokinetic modeling, pharmacokinetic-pharmacodynamic modeling, dosing schedule optimization, food effect, drug formulation, interindividual variability, forecast uncertainty, drug candidate selection
- MeSH terms
- Absorption, Animals, Biological Transport, Active, Drug Interactions, Food, Humans, Models, Biological, Drug Design, Xenobiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
